Julie Renee Brahmer
#114,469
Most Influential Person Now
Julie Renee Brahmer's AcademicInfluence.com Rankings
Julie Renee Brahmermedical Degrees
Medical
#1612
World Rank
#1970
Historical Rank
Oncology
#76
World Rank
#80
Historical Rank
Julie Renee Brahmerphilosophy Degrees
Philosophy
#4919
World Rank
#7598
Historical Rank
Logic
#2280
World Rank
#3241
Historical Rank
Download Badge
Medical Philosophy
Julie Renee Brahmer's Degrees
- Doctorate Medicine University of Nebraska Medical Center
Why Is Julie Renee Brahmer Influential?
(Suggest an Edit or Addition)Julie Renee Brahmer's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. (2012) (10640)
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. (2015) (7370)
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. (2015) (6804)
- Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. (2016) (6764)
- Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. (2012) (6726)
- Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. (2006) (5665)
- Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. (2010) (2647)
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden (2018) (2193)
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. (2018) (2082)
- Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. (2014) (2043)
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy (2014) (1984)
- Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. (2019) (1372)
- Neoadjuvant PD‐1 Blockade in Resectable Lung Cancer (2018) (1203)
- Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. (2009) (1095)
- Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. (2015) (1015)
- Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. (2019) (907)
- American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. (2009) (870)
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary. (2018) (827)
- Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. (2017) (765)
- Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). (2017) (640)
- Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. (2017) (601)
- Genome-wide cell-free DNA fragmentation in patients with cancer (2019) (541)
- Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors (2011) (510)
- Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody (2012) (502)
- Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study. (2018) (481)
- Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. (2016) (455)
- Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. (2016) (414)
- Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. (2015) (400)
- Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. (2016) (380)
- Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599 (2005) (379)
- Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer (2014) (377)
- Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. (2015) (373)
- First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers (2019) (364)
- Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases (2018) (363)
- Management of Immunotherapy-Related Toxicities, Version 1.2019. (2019) (363)
- Immune-related adverse events of checkpoint inhibitors (2020) (360)
- Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. (2008) (350)
- Alterations of immune response of non-small cell lung cancer with Azacytidine (2013) (335)
- Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. (2008) (323)
- Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab (2019) (316)
- Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab (2016) (315)
- Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. (2017) (284)
- Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer (2018) (280)
- Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. (2022) (276)
- 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. (2011) (253)
- Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC) (2018) (241)
- Pneumonitis in Non–Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors (2018) (236)
- A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non–Small Cell Lung Cancer (2013) (232)
- Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. (2010) (222)
- Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50% (2021) (219)
- Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. (2017) (219)
- Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. (2008) (218)
- NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. (2020) (217)
- Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma. (2017) (215)
- EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. (2019) (213)
- Scientific Advances in Lung Cancer 2015 (2016) (207)
- Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non–Small Cell Lung Cancer (2015) (207)
- Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. (2012) (205)
- Nivolumab in NSCLC: latest evidence and clinical potential (2015) (201)
- Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. (2020) (197)
- Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. (2019) (194)
- The emerging role of epigenetic therapeutics in immuno-oncology (2019) (193)
- Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. (2014) (189)
- Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients (2007) (182)
- Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer (2021) (180)
- Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer (2013) (175)
- Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. (2006) (173)
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events (2021) (168)
- Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has come. (2005) (163)
- Epigenetic therapy inhibits metastases by disrupting premetastatic niches (2020) (160)
- Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. (2018) (159)
- Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer. (2020) (158)
- Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer. (2019) (154)
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC) (2018) (154)
- Nivolumab: targeting PD-1 to bolster antitumor immunity. (2015) (152)
- Harnessing the immune system for the treatment of non-small-cell lung cancer. (2013) (147)
- Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. (2019) (146)
- Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). (2015) (143)
- Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers (2021) (138)
- Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). (2015) (137)
- Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer (2009) (135)
- The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2) (2017) (134)
- Delayed Diagnosis and Elevated Mortality in an Urban Population With HIV and Lung Cancer: Implications for Patient Care (2006) (133)
- Nivolumab Plus Erlotinib in Patients With EGFR‐Mutant Advanced NSCLC (2018) (131)
- The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA (2016) (131)
- Comparative Pharmacokinetics of Weekly and Every-Three-Weeks Docetaxel (2004) (126)
- Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. (2021) (124)
- Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial. (2019) (123)
- Phase 2 Study of Pemetrexed and Itraconazole as Second-Line Therapy for Metastatic Nonsquamous Non–Small-Cell Lung Cancer (2013) (118)
- Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation (2019) (117)
- Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. (2009) (113)
- Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer (2020) (111)
- First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status. (2014) (106)
- Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. (2018) (104)
- CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. (2006) (101)
- Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. (2016) (99)
- Asking the right questions: investigating needs assessments and health-related quality-of-life questionnaires for use in oncology clinical practice (2007) (97)
- Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies. (2010) (94)
- Nivolumab (Nivo) + platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with <1% tumor PD-L1 expression: Results from CheckMate 227. (2018) (93)
- Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC. (2014) (90)
- Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis. (2014) (89)
- Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Combination With Platinum-Based Doublet Chemotherapy (PT-DC) in Advanced Non-Small Cell Lung Cancer (NSCLC) (2014) (89)
- [American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer]. (2010) (88)
- Immune Checkpoint Modulation for Non–Small Cell Lung Cancer (2015) (88)
- The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity (2018) (87)
- Body Mass Index and Its Association with Clinical Outcomes for Advanced Non–Small-Cell Lung Cancer Patients Enrolled on Eastern Cooperative Oncology Group Clinical Trials (2013) (87)
- Abstract CT001: Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial (2016) (86)
- Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy. (2014) (85)
- Detection and characterization of lung cancer using cell-free DNA fragmentomes (2021) (83)
- Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. (2003) (82)
- Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort. (2015) (81)
- OA 17.06 Updated Analysis of KEYNOTE-024: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced NSCLC With PD-L1 TPS ≥50% (2017) (80)
- First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small Cell Lung Cancer: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. (2021) (79)
- Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy (2019) (79)
- CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC. (2016) (78)
- LBA51 KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50% (2020) (78)
- Genetic and Proteomic Features Associated with Survival after Treatment with Erlotinib in First-Line Therapy of Non-small Cell Lung Cancer in Eastern Cooperative Oncology Group 3503 (2010) (77)
- Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (2011) (75)
- Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC). (2021) (74)
- Survival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC). (2013) (73)
- Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients (2006) (72)
- The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis. (2019) (72)
- Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer (2020) (71)
- Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial. (2013) (70)
- Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade (2017) (70)
- Abstract CT078: Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) + ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): identification of TMB cutoff from CheckMate 568 (2018) (69)
- A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy‐Naïve Advanced or Metastatic Nonsquamous Non‐Small Cell Lung Cancer (2018) (68)
- Immunotherapy in the treatment of non-small cell lung cancer. (2014) (67)
- Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non–Small Cell Lung Cancer (2019) (66)
- A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events. (2018) (66)
- Prognostic Models to Predict Survival in Non–Small-Cell Lung Cancer Patients Treated with First-Line Paclitaxel and Carboplatin with or without Bevacizumab (2012) (65)
- Clinical Activity, Tolerability, and Long-term Follow-up of Durvalumab in Patients With Advanced NSCLC. (2019) (64)
- Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non-Small-Cell Lung Cancer. (2019) (63)
- Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer. (2019) (61)
- Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 (2020) (60)
- Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057. (2018) (60)
- Sex Differences in Outcome with Bevacizumab Therapy: Analysis of Patients with Advanced-Stage Non-small Cell Lung Cancer Treated with or without Bevacizumab in Combination with Paclitaxel and Carboplatin in the Eastern Cooperative Oncology Group Trial 4599 (2011) (58)
- Symptoms, supportive care needs, and function in cancer patients: how are they related? (2008) (58)
- Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort. (2019) (58)
- A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours (2013) (57)
- Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). (2014) (56)
- Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer. (2009) (55)
- Bevacizumab Maintenance in Patients with Advanced Non–Small-Cell Lung Cancer, Clinical Patterns, and Outcomes in the Eastern Cooperative Oncology Group 4599 Study: Results of An Exploratory Analysis (2012) (55)
- Needs assessments can identify scores on HRQOL questionnaires that represent problems for patients: an illustration with the Supportive Care Needs Survey and the QLQ-C30 (2010) (54)
- New Strategies in Lung Cancer: Epigenetic Therapy for Non–Small Cell Lung Cancer (2014) (54)
- Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥50% enrolled in KEYNOTE-024. (2017) (53)
- Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1. (2020) (52)
- Safety and Effectiveness of Bevacizumab-Containing Treatment for Non–Small-Cell Lung Cancer: Final Results of the ARIES Observational Cohort Study (2014) (52)
- Safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies (2008) (51)
- Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. (2022) (51)
- Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern (2017) (51)
- Abstract CT077: Five-year follow-up from the CA209-003 study of nivolumab in previously treated advanced non-small cell lung cancer (NSCLC): Clinical characteristics of long-term survivors (2017) (50)
- New Strategies in Lung Cancer: Translating Immunotherapy into Clinical Practice (2014) (50)
- Abstract CT003: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial (2021) (49)
- Emerging treatments for choroidal metastases. (2011) (49)
- Immune checkpoint blockade: the hope for immunotherapy as a treatment of lung cancer? (2014) (48)
- A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC). (2015) (48)
- Phase II Study of Pemetrexed-Gemcitabine Combination in Patients with Advanced-Stage Non-Small Cell Lung Cancer (2004) (48)
- Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road Wisely. (2020) (48)
- PD-1-targeted immunotherapy: recent clinical findings. (2012) (47)
- A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts). (2013) (47)
- OA03.05 Analysis of Early Survival in Patients with Advanced Non-Squamous NSCLC Treated with Nivolumab vs Docetaxel in CheckMate 057 (2017) (45)
- LBA3 Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC): CheckMate 227 - part 2 final analysis (2019) (43)
- Phase 1/2 study of the safety and clinical activity of durvalumab in patients with non-small cell lung cancer (NSCLC) (2016) (42)
- Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatography-tandem mass spectrometry. (2002) (42)
- What lies within: novel strategies in immunotherapy for non-small cell lung cancer. (2013) (41)
- Concordance of cancer patients’ function, symptoms, and supportive care needs (2009) (41)
- Nivolumab (nivo) in patients (pts) with advanced (adv) NSCLC and central nervous system (CNS) metastases (mets). (2016) (40)
- Updated safety and efficacy of durvalumab (MEDI4736), an anti-PD-L 1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort (2016) (40)
- Prospective correlative assessment of biomarkers in E4599 randomized phase II/III trial of carboplatin and paclitaxel ± bevacizumab in advanced non-small cell lung cancer (NSCLC). (2006) (39)
- First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression. (2015) (38)
- A randomized discontinuation phase II trial of ridaforolimus in non-small cell lung cancer (NSCLC) patients with KRAS mutations. (2012) (38)
- First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status (2014) (38)
- PrE0505: Phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (MPM)—A PrECOG LLC study. (2020) (38)
- Efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC): Results from a phase II study (2007) (37)
- Imaging δ- and μ-Opioid Receptors by PET in Lung Carcinoma Patients (2007) (37)
- P2.36: Nivolumab (nivo) in Patients (pts) With Advanced (adv) NSCLC and Central Nervous System (CNS) Metastases (mets): Track: Immunotherapy. (2016) (36)
- Neoadjuvant nivolumab in early-stage, resectable non-small cell lung cancers. (2017) (36)
- Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial (2021) (35)
- Nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced NSCLC: CheckMate 017/057 2-y update and exploratory cytokine profile analyses. (2016) (35)
- OA14.01 KEYNOTE-024 3-Year Survival Update: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer (2019) (34)
- 1229PDSMOKING HISTORY AND RESPONSE TO NIVOLUMAB IN PATIENTS WITH ADVANCED NSCLCS. (2014) (34)
- C-fos assessment as a marker of anti-epidermal growth factor receptor effect. (2006) (34)
- Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1 (2019) (33)
- Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis (2019) (33)
- Genetic variants in angiogenesis pathway associated with clinical outcome in NSCLC patients (pts) treated with bevacizumab in combination with carboplatin and paclitaxel: Subset pharmacogenetic analysis of ECOG 4599. (2009) (33)
- OA14.04 Five-Year Outcomes From the Randomized, Phase 3 Trials CheckMate 017/057: Nivolumab vs Docetaxel in Previously Treated NSCLC (2019) (31)
- O-086a Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C)with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial — E4599 (2005) (31)
- Classification by Mass Spectrometry Can Accurately and Reliably Predict Outcome in Patients with Non-small Cell Lung Cancer Treated with Erlotinib-Containing Regimen (2009) (31)
- Retrospective study of clinical and radiographic risk factors associated with early onset, severe pulmonary hemorrhage in bevacizumab-treated patients with advanced non-small cell lung cancer (NSCLC). (2006) (30)
- Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors (2008) (30)
- Chronic immune checkpoint inhibitor pneumonitis (2020) (29)
- Clinical activity and safety of anti-PD1 (BMS-936558, MDX-1106) in patients with advanced non-small-cell lung cancer (NSCLC). (2012) (29)
- Differential effect of age on survival in advanced NSCLC in women versus men: analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab. (2012) (28)
- Systemic Therapy, Clinical Outcomes, and Overall Survival in Locally Advanced or Metastatic Pulmonary Carcinoid: A Brief Report (2014) (28)
- A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer (2013) (27)
- Five National Cancer Institute–designated cancer centers' data collection on racial/ethnic minority participation in therapeutic trials (2014) (27)
- Baseline tumour measurements predict survival in advanced non-small cell lung cancer (2013) (27)
- Preliminary safety and effectiveness of bevacizumab (BV) based treatment in subpopulations of patients (pts) with non-small cell lung cancer (NSCLC) from the ARIES study: A bevacizumab (BV) treatment observational cohort study (OCS). (2009) (27)
- P2.35: Nivolumab vs Docetaxel in Advanced NSCLC: CheckMate 017/057 2-Y Update and Exploratory Cytokine Profile Analysis: Track: Immunotherapy. (2016) (27)
- Phase II experience with MDX-1106 (Ono-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies. (2009) (27)
- PD-1/PD-L1 pathway as a target for cancer immunotherapy: Safety and clinical activity of BMS-936559, an anti-PD-L1 antibody, in patients with solid tumors. (2012) (26)
- Neoadjuvant nivolumab in resectable non-small cell lung cancer: Extended follow-up and molecular markers of response. (2019) (26)
- Imaging delta- and mu-opioid receptors by PET in lung carcinoma patients. (2007) (25)
- KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50% (2016) (24)
- Chemotherapy for advanced stage non-small cell lung cancer. (2008) (24)
- Heterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma (2016) (24)
- Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503). (2014) (24)
- Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes (2021) (24)
- Long-term Survival, Clinical Activity, and Safety of Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC) (2014) (23)
- Preliminary treatment patterns and safety outcomes for non-small cell lung cancer (NSCLC) from ARIES, a bevacizumab treatment observational cohort study (OCS) (2008) (22)
- Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer. (2016) (22)
- “Who Should Receive Epidermal Growth Factor Receptor Inhibitors for Non-Small Cell Lung Cancer and When?” (2007) (21)
- Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies. (2009) (21)
- A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer. (2013) (21)
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates (2023) (20)
- Clinical mutational profiling of 1006 lung cancers by next generation sequencing. (2017) (20)
- KEYNOTE-024: Phase III trial of pembrolizumab (MK-3475) vs platinum-based chemotherapy as first-line therapy for patients with metastatic non-small cell lung cancer (NSCLC) that expresses programmed cell death ligand 1 (PD-L1). (2015) (20)
- Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer. (2007) (20)
- Long-term outcomes with nivolumab (Nivo) vs docetaxel (Doc) in patients (Pts) with advanced (Adv) NSCLC: CheckMate 017 and CheckMate 057 2-y update (2016) (20)
- 1301PDThree-year follow-up from CheckMate 017/057: Nivolumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) (2017) (20)
- Targeting the epidermal growth factor receptor in non-small-cell lung cancer: Who, which, when, and how? (2007) (20)
- Nivolumab (N) plus ipilimumab (I) as first-line (1L) treatment for advanced (adv) NSCLC: 2-yr OS and long-term outcomes from CheckMate 012. (2017) (19)
- Adjuvant treatment in non-small cell lung cancer: Where are we now? (2006) (19)
- A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB–IIIA resectable NSCLC (2017) (19)
- Clinical outcomes in elderly patients with advanced non-small cell lung cancer: results from ARIES, a bevacizumab observational cohort study. (2015) (18)
- Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline (2022) (18)
- Safety and Efficacy of First-Line Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC) (2014) (18)
- P2.16-03 CheckMate 816: A Phase 3 Trial of Neoadjuvant Nivolumab Plus Ipilimumab or Chemotherapy vs Chemotherapy in Early-Stage NSCLC (2018) (17)
- Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers (2021) (17)
- Association of severe lymphopenia and disease progression in unresectable locally advanced non-small cell lung cancer treated with definitive chemoradiation and immunotherapy. (2021) (17)
- Five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLC (2020) (16)
- PL04a.01: Health-Related Quality of Life for Pembrolizumab vs Chemotherapy in Advanced NSCLC with PD-L1 TPS ≥50%: Data from KEYNOTE-024 (2017) (16)
- Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer (2018) (16)
- Carboplatin in the Treatment of Small Cell Lung Cancer (1998) (16)
- The Evolving Role of Nivolumab in Non-Small-Cell Lung Cancer for Second-Line Treatment: A New Cornerstone for Our Treatment Algorithms. Results From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology. (2016) (15)
- Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline (2022) (15)
- Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227. (2021) (15)
- Neoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer. (2016) (15)
- Targeting the Immune System in the Treatment of Non-Small-Cell Lung Cancer (2013) (15)
- PD3-3-5: Outcomes for elderly advanced stage non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P): Analysis of Eastern Cooperative Oncology Group (ECOG) 4599 study (2007) (15)
- An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227) (2015) (15)
- A phase III comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus docetaxel in patients with previously treated advanced or metastatic squamous cell non-small cell lung cancer (NSCLC). (2013) (15)
- Immunotherapy for Lung Cancer: No Longer an Abstract Concept (2016) (14)
- NSCLC, early stageNeoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer (2016) (14)
- Abstract CT195: Long-term survival outcomes with nivolumab (NIVO) in pts with previously treated advanced non-small cell lung cancer (NSCLC): Impact of early disease control and response (2019) (14)
- Abstract NG01: Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer (2017) (14)
- Safety and clinical activity of first-line durvalumab in advanced NSCLC: Updated results from a Phase 1/2 study. (2017) (14)
- Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer. (2018) (14)
- Challenge of Rechallenge: When to Resume Immunotherapy Following an Immune-Related Adverse Event. (2019) (14)
- ORAL01.03: CheckMate 012: Safety and Efficacy of First‐Line Nivolumab and Ipilimumab in Advanced NSCLC: Topic: Medical Oncology (2016) (14)
- MA 09.08 Receipt of Chest Radiation and Immune-Related Pneumonitis in Patients with NSCLC Treated with Anti-PD-1/PD-L1 (2017) (13)
- OA 17.03 First-Line Nivolumab plus Platinum-Based Doublet Chemotherapy for Advanced NSCLC: CheckMate 012 3-Year Update (2017) (13)
- Management of malignant pleural effusion (2008) (13)
- Pleural mesothelioma metastatic to tongue. (2007) (13)
- Current challenges of hematologic complications due to immune checkpoint blockade: a comprehensive review (2021) (13)
- Safety and efficacy of pembrolizumab (Pembro) monotherapy in elderly patients (Pts) with PD-L1-positive advanced NSCLC: Pooled analysis from KEYNOTE-010, -024, and -042. (2019) (13)
- A pooled analysis of two phase II trials evaluating metformin plus platinum-based chemotherapy in advanced non-small cell lung cancer. (2019) (13)
- Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response. (2012) (13)
- Outcomes for elderly advanced stage non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P): Analysis of Eastern Cooperative Oncology Group (ECOG) 4599 study (2007) (12)
- 417OPhase 3, randomized trial (CheckMate 057) of nivolumab vs docetaxel in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): subgroup analyses and patient reported outcomes (PROs) (2015) (12)
- A phase 1 study of MORAb-009, a monoclonal antibody against mesothelin in pancreatic cancer, mesothelioma and ovarian adenocarcinoma (2007) (12)
- Non‐small cell lung cancer: Adjuvant and neo‐adjuvant chemotherapy (2007) (12)
- Checkmate 816: A phase 3, randomized, open-label trial of nivolumab plus ipilimumab vs platinum-doublet chemotherapy as neoadjuvant treatment for early-stage NSCLC. (2017) (12)
- Immune-related (IR)-pneumonitis during the COVID-19 pandemic: multidisciplinary recommendations for diagnosis and management (2020) (12)
- 3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses (2015) (11)
- 1054PDNIVOLUMAB (ANTI-PD-1; BMS-936558, ONO-4538) IN COMBINATION WITH PLATINUM-BASED DOUBLET CHEMOTHERAPY (PT-DC) OR ERLOTINIB (ERL) IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC). (2014) (11)
- Clinical mutational profiling of 1006 lung cancers by next generation sequencing (2017) (11)
- Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matter (2007) (11)
- Using Immune Checkpoint Inhibitors in Lung Cancer. (2016) (10)
- Baseline (BL) radiographic characteristics and severe pulmonary hemorrhage (SPH) in bevacizumab (BV)-treated non-small cell lung cancer (NSCLC) patients (pt): Results from ARIES, an observational cohort study (OCS). (2010) (10)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
- OA 12.01 The Preclinical and Clinical Activity of Poziotinib, a Potent, Selective Inhibitor of EGFR Exon 20 Mutant NSCLC (2017) (10)
- Abstract CT077: Nivolumab (nivo) + ipilimumab (ipi) vs platinum-doublet chemotherapy (PT-DC) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): initial results from CheckMate 227 (2018) (10)
- 144TiPCheckMate 227: A randomized, open-label phase 3 trial of nivolumab, nivolumab plus ipilimumab, or nivolumab plus chemotherapy versus chemotherapy in chemotherapy-naïve patients with advanced non-small cell lung cancer (NSCLC) (2017) (10)
- 3094 Nivolumab (NIVO) safety profile: Summary of findings from trials in patients (pts) with advanced squamous (SQ) non-small cell lung cancer (NSCLC) (2015) (9)
- Phase I dose escalation study of recombinant interleukin-21 (rIL-21; BMS-982470) in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced or metastatic solid tumors. (2013) (9)
- Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227 (2022) (9)
- Overall health status (HS) in patients (pts) with advanced (adv) non-squamous (NSQ) NSCLC treated with nivolumab (nivo) or docetaxel (doc) in CheckMate 057 (2016) (9)
- Menopausal status of women may affect survival in advanced NSCLC: Analysis of recent Eastern Cooperate Oncology Group (ECOG) studies using age of 60 years or older as a surrogate marker: P1-052 (2007) (9)
- Safety and activity of durvalumab + tremelimumab in immunotherapy (IMT)-pretreated advanced NSCLC patients. (2018) (9)
- CYP 3 A Phenotyping Approach to Predict Systemic Exposure to EGFR Tyrosine Kinase Inhibitors (9)
- Updated safety and clinical activity of durvalumab monotherapy in previously treated patients with stage IIIB/IV NSCLC. (2017) (9)
- Pleural fluid secondary to pulmonary cryptococcal infection: a case report and review of the literature (2019) (9)
- Abstract A047: Safety and clinical activity of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC) (2016) (8)
- Oligometastatic Adenocarcinoma of the Lung: A Therapeutic Opportunity for Long-Term Survival (2015) (8)
- Phase II trial of gemcitabine/carboplatin followed by paclitaxel in patients with performance status=2,3 or other significant co-morbidity (HIV infection or s/p organ transplantation) in advanced non-small cell lung cancer. (2008) (8)
- JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted Listeria monocytogenes–Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies (2020) (8)
- Abstract B143: A phase 1a/1b study of FPA008 in combination with nivolumab in patients with selected advanced cancers (2016) (8)
- 3097 Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC) (2015) (8)
- Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling (2020) (8)
- Multicenter phase II study of cetuximab (C) with concomitant radiotherapy (RT) followed by consolidation chemotherapy (CT) in locally advanced non-small cell lung cancer (NSCLC). (2011) (8)
- OA03.01 First-Line Nivolumab Monotherapy and Nivolumab plus Ipilimumab in Patients with Advanced NSCLC: Long-Term Outcomes from CheckMate 012 (2017) (8)
- Molecular analysis-directed, international, phase III trial in patients with advanced non-small-cell lung cancer. (2013) (7)
- Immune Checkpoint Therapy in Non–Small Cell Lung Cancer (2016) (7)
- 3010 Phase, randomized trial (CheckMate 057) of nivolumab (NIVO) vs docetaxel (DOC) in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): Subgroup analyses and patient reported outcomes (PROs) (2015) (7)
- Nivolumab (Nivo) + Ipilimumab (Ipi) vs Platinum-Doublet Chemotherapy (Chemo) as First-line (1L) Treatment (Tx) for Advanced Non-Small Cell Lung Cancer (NSCLC): Safety Analysis and Patient-Reported Outcomes (PROs) From CheckMate 227. (2018) (7)
- DREAM3R: Durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma—A phase 3 randomized trial. (2021) (6)
- Anti-Programmed Death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in Patients (PTS) with Advanced Solid Tumors: Clinical Activity, Safety, and Molecular Markers (2012) (6)
- Anti-PD-1 (BMS-936558/MDX-1106/ONO-4538) in Patients With Advanced Solid Tumors: Clinical Activity, Safety, and Molecular Markers (2012) (6)
- Updated overall survival and safety profile of durvalumab monotherapy in advanced NSCLC. (2018) (6)
- O.02 Long-term Survival Outcomes with Nivolumab (NIVO) in Pts with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC): Impact of Early Disease Control and Response (2019) (6)
- A phase II multicenter study of aflibercept (AFL) in combination with cisplatin (C) and pemetrexed (P) in patients with previously untreated advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC). (2012) (6)
- Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy (2022) (6)
- Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC (2015) (6)
- Clinical Practice Guideline Update on Chemotherapy for Stage IV Non – Small-Cell Lung Cancer (2009) (5)
- Pathology quiz case 1. Metastatic mesothelioma involving the tongue. (2006) (5)
- Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response. (2012) (5)
- Phase I/II dose-escalation and expansion study of FLX475 alone and in combination with pembrolizumab in advanced cancer. (2019) (5)
- P1.01-02 Long-Term Outcomes with First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up from CheckMate 012 (2018) (5)
- PD3-3-8: A phase II study of continuous daily sunitinib dosing in patients with previously-treated advanced non-small cell lung cancer (NSCLC) (2007) (5)
- Reply: Regulatory T cells—an important target for cancer immunotherapy (2014) (4)
- Population pharmacokinetic (PK)-pharmacodynamic (PD) model for gefitinib in cancer patients (2005) (4)
- Development of MEDI4736, an anti-programmed cell death ligand 1 (PD-L1) antibody, as monotherapy or in combination with other therapies in the treatment of non-small cell lung cancer (NSCLC) (2014) (4)
- Abstract CT169: Poziotinib administered twice daily improves safety and tolerability in patients with EGFR or HER2 exon 20 mutant NSCLC(ZENITH20-5) (2021) (4)
- Safety of First-line Nivolumab Plus Ipilimumab in Patients With Metastatic Non-Small Cell Lung Cancer: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817. (2022) (4)
- A randomized phase II trial comparing pulsed erlotinib before or after carboplatin and paclitaxel in patients with stage IIIB or IV non-small cell lung cancer (2007) (4)
- Clinical Activity and Safety of Anti-Programmed Death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in Patients (PTS) with Advanced Non-Small Cell Lung Cancer (NSCLC) (2012) (4)
- OA05.06 CheckMate 227: Patient-Reported Outcomes of First-Line Nivolumab + Ipilimumab in High Tumor Mutational Burden Advanced NSCLC (2018) (4)
- Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma—a phase 3 randomised trial (2022) (3)
- Multisystem immune-related adverse events from anti-PD-1/PD-L1 in patients with lung cancer: Incidence, clinical patterns, management, and outcomes. (2019) (3)
- MA11.11 STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC (2019) (3)
- 1325PCLINICAL ACTIVITY AND SAFETY OF MEDI4736, AN ANTI-PROGRAMMED CELL DEATH-LIGAND 1 (PD-L1) ANTIBODY, IN PATIENTS WITH NON-SMALL CELL LUNG CANCER. (2014) (3)
- A phase I study of MORab-009, a monoclonal antibody against mesothelin, in mesothelioma, pancreatic and ovarian cancer (2008) (3)
- Adjuvant therapy for resected non-small-cell lung cancer: Past, present, and future (2005) (3)
- Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer. (2016) (3)
- Gender-Related Differences in Lung Cancer (2018) (3)
- Phase II Study of Continuous Daily Sunitinib Dosing in Patients with Previously Treated Advanced Non–Small-Cell Lung Cancer (NSCLC) (2007) (3)
- Effectiveness of bevacizumab exposure beyond disease progression in patients with non–small‐cell lung cancer: analyses of the ARIES observational cohort study (2016) (3)
- Targeting the immune system for management of NSCLC: the revival? (2013) (3)
- 67P Survival of responders to nivolumab (NIVO) + ipilimumab (IPI) as first-line treatment for advanced NSCLC in CheckMate 227, part 1 (2020) (3)
- Mutation status and postresection survival of patients with non-small cell lung cancer brain metastasis: implications of biomarker-driven therapy. (2021) (3)
- Randomized Phase 2 Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Single-Agent Chemotherapy in Previously Treated KRAS Mutant Advanced Non-Small Cell Lung Cancer (NSCLC) (2014) (3)
- Pembrolizumab in Non-Small-Cell Lung Cancer. (2017) (3)
- Second-line therapy for advanced non-small-cell lung cancer (2006) (3)
- 9020 POSTER DISCUSSION Use of Bevacizumab (BV) After Induction Therapy is Associated With Survival Benefit in Patients (pts) With Non-small Cell Lung Cancer (NSCLC) in the ARIES Observational Cohort Study (OCS) (2011) (3)
- Case for Stopping Targeted Therapy When Lung Cancer Progresses on Treatment in Hospice-Eligible Patients. (2017) (3)
- Abstract CT079: Neoadjuvant PD-1 blockade in resectable lung cancer (2018) (3)
- Persistent mutation burden drives sustained anti-tumor immune responses (2023) (3)
- 188P Treatment switching–adjusted overall survival (OS) in KEYNOTE-024: First-line pembrolizumab versus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) (2018) (2)
- Human immunodeficiency virus and lung cancer: differences in presentation and clinical course. (2005) (2)
- Immune Checkpoint Inhibitors Improve Survival and Local Control in Patients With Spine Metastasis After Stereotactic Body Radiotherapy. (2021) (2)
- Outcomes of EGFR-mutant lung adenocarcinomas (AC) that transform to small cell lung cancer (SCLC). (2018) (2)
- 4O Nivolumab (NIVO) + ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 part 1: Efficacy by KRAS, STK11, and KEAP1 mutation status (2021) (2)
- P2.04-24 Transcriptional Profiling of Neoantigen Specific T Cells in Resectable NSCLC Treated with Neoadjuvant Anti-PD-1 (2019) (2)
- Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: an Observational, Pharmacovigilance Study. (2022) (2)
- Validation of proteomic classifier for clinical benefit from erlotinib as first line treatment for advanced non-small cell lung cancer (ECOG 3503) (2007) (2)
- Patient-reported outcomes and managed care decisions: Quality of life and related components (2002) (2)
- Anti-PD-1 for patients with leptomeningeal metastasis from advanced solid tumors: Efficacy, safety, and biomarkers of response. (2020) (2)
- Preliminary immunogenicity, safety, and efficacy of JNJ-64041757 (JNJ-757) in non-small cell lung cancer (NSCLC): Results from two phase 1 studies. (2019) (2)
- Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC (2021) (2)
- PS-3Japan subset of Phase III study KEYNOTE-024: Pembrolizumab for PD-L1 TPS > =50%, treatment-naïve NSCLC (2017) (2)
- 122MO Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): Intracranial and systemic outcomes from CheckMate 227 Part 1 (2021) (2)
- KEYNOTE‐024 Update: Pembrolizumab vs Platinum‐Based Chemotherapy for Advanced NSCLC with PD‐L1 Tumor Proportion Score ≥50%: PS3 (2018) (2)
- Abstract 4619: Epigenetic therapy and sensitization of lung cancer to immunotherapy. (2013) (2)
- Abstract CT012: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment for resectable (IB-IIIA) non-small cell lung cancer (NSCLC): Event-free survival (EFS) results from the phase 3 CheckMate 816 trial (2022) (2)
- 788 Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety and cerebrospinal fluid biomarkers (2020) (2)
- P3.02c-030 Use of a 200-Mg Fixed Dose of Pembrolizumab for the Treatment of Advanced Non–Small Cell Lung Cancer (NSCLC): Topic: IT (2017) (2)
- Dual inhibition of the epidermal growth factor receptor (EGFR) pathway with the combination of cetuximab and erlotinib: A phase I study in patients with advanced solid malignancies (2007) (2)
- Genome-wide cell-free DNA fragmentation profiling for early cancer detection. (2019) (2)
- Bevacizumab: Analysis of clinical benefit in females across trials in colorectal cancer and non-small cell lung cancer (2007) (2)
- Nivolumab (NIVO) plus ipilimumab (IPI) with two cycles of chemotherapy (chemo) in first-line metastatic non-small cell lung cancer (NSCLC): CheckMate 568 Part 2. (2020) (2)
- MA04.11 Neoantigen Targeting and T Cell Reshaping in Resectable NSCLC Patients Treated with Neoadjuvant PD-1 Blockade (2018) (1)
- Integrative Analysis of Checkpoint Blockade Response in Advanced Non-Small Cell Lung Cancer (2022) (1)
- Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small cell lung cancer: a pooled analysis. (2022) (1)
- Evaluation of gefitinib biological effects in patients with solid tumors amenable to sequential biopsies-Final results. (2006) (1)
- Author Correction: Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers (2021) (1)
- Optimizing the dose and schedule of anti-vascular endothelial growth factor antibodies in non-small-cell lung cancer. (2008) (1)
- Clinical Significance of Plasma CD9-Positive Exosomes in HIV Seronegative and Seropositive Lung Cancer Patients (2021) (1)
- Identifying and addressing the toxicity of checkpoint inhibitors in lung cancer. (2016) (1)
- Advanced pulmonary carcinoid (APC): 20-year experience at Johns Hopkins (JH). (2013) (1)
- 6525 POSTER Phase II study investigating the efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC) (2007) (1)
- MA07.05 Survivors from Anti-PD-(L)1 Immunotherapy in NSCLC: Clinical Features, Survival Outcomes and Long-term Toxicities (2021) (1)
- Lung Cancer : Translational and Emerging Therapies (2007) (1)
- OA03.03 Nivolumab (NIVO) + ipilimumab (IPI) Versus Platinum-Doublet Chemotherapy (Chemo) as First-Line (1L) Treatment for Advanced Non-Small Cell Lung Cancer (aNSCLC): 3-year Update from CheckMate 227 Part 1 (2021) (1)
- Advances in the Treatment of Brain Metastases (2016) (1)
- 185TiP A phase Ib dose-escalation study evaluating trastuzumab deruxtecan (T-DXd) and durvalumab in combination with chemotherapy as first-line treatment in patients with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (DESTINY-Lung03) (2021) (1)
- Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy (2022) (1)
- Comprehensive modeling of longitudinal circulating tumor DNA dynamics to predict clinical response to first-line immunotherapy and chemoimmunotherapy in advanced non-small cell lung cancer. (2020) (1)
- P2.07-058 First-In-Human Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, for Non-Small Cell Lung Cancer (2017) (1)
- A phase I study of BMS-936558 in combination with gemcitabine/cisplatin, pemetrexed/cisplatin, or carboplatin/paclitaxel in patients with treatment-naive, stage IIIB/IV non-small-cell lung cancer. (2012) (1)
- FP05.02 A Biomarker-Directed, Multi-Center Phase II Study of Molecular Response Adaptive Immuno-Chemotherapy in Lung Cancer (2021) (1)
- 362 Binding of gefitinib (ZD1839) to human plasma proteins: in vitro and clinical pharmacokinetic (PK) studies (2004) (1)
- Genome-wide cell-free DNA fragmentation in patients with cancer (2019) (1)
- Anti-RA33 antibodies are present in a subset of patients with immune checkpoint inhibitor-induced inflammatory arthritis (2021) (1)
- Migration to next-generation sequencing and the identification of RET and ROS1 rearrangements plus PTEN and MET protein expression in tumor specimens from patients with lung adenocarcinomas: Lung Cancer Mutation Consortium (LCMC 2.0). (2015) (1)
- Early shifts in immune cell subsets to predict response to immune checkpoint blockade in non-small cell lung cancer (NSCLC). (2019) (1)
- Impact of Checkpoint Inhibitor Pneumonitis on Survival in Non-Small Cell Lung Cancer Patients receiving Immune Checkpoint Immunotherapy. (2018) (1)
- Patients' guide to lung cancer (2011) (1)
- Sex-specific differences in immunogenomic features of response to immune checkpoint blockade (2022) (1)
- Correction to: persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1 (2019) (1)
- P-391 How dedicated Positron Emission Tomography-CT (PET-CT) affects the diagnostic and therapeutic approaches to patients managed by a Multimodality Thoracic Oncology Group (2005) (0)
- OA12.01 Genomic and Immune Cell Landscape of Response to Chemo-Immunotherapy in Malignant Pleural Mesothelioma (2021) (0)
- Why is it so difficult to enroll patients in clinical trials (2014) (0)
- DynamicsofTumorand ImmuneResponsesduring Immune Checkpoint Blockade in Non–Small Cell Lung Cancer (2019) (0)
- Systemic and intracranial outcomes with first-line nivolumab plus ipilimumab in patients with metastatic non-small cell lung cancer and baseline brain metastases from CheckMate 227 Part 1. (2023) (0)
- Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in PD-(L)1-Monotherapy Pretreated, Advanced Non-Small Cell Lung Cancer: Results From a Phase 1b Clinical Trial. (2023) (0)
- Lung Cancer Survival Rates Improving With Nivolumab (2017) (0)
- An Oncology Urgent Care Clinic for the Management of Immune-Related Adverse Events: A Descriptive Analysis (2022) (0)
- MA11.10 Peripheral T Cell Repertoire Evolution in Resectable NSCLC Treated with Neoadjuvant PD-1 Blockade (2019) (0)
- C-102 Early stage non small cell lung cancer (2019) (0)
- Abstract 3468: Immunoproteasome expression and checkpoint blockade response in advanced non-small cell lung cancer (2023) (0)
- Definitive Chemoradiation and Durvalumab Consolidation for Locally Advanced, Unresectable KRAS-mutated Non-Small Cell Lung Cancer. (2022) (0)
- Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non-Small Cell Lung Cancer. (2023) (0)
- QIM21-090: The Expanding Role of an Oncology Urgent Care Clinic for the Management of Immune-Related Adverse Events (2021) (0)
- NCCN: Continuing Education (2019) (0)
- Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer (2018) (0)
- Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. (2023) (0)
- Multimodality approach to stage III NSCLC: Current state of knowledge (2006) (0)
- Results from intermittent and continuous dosing schedules with sunitinib (SU) in previously treated, advanced non–small-cell lung cancer (NSCLC) (2008) (0)
- Metastatic mesothelioma involving the tongue (2006) (0)
- Adjuvant therapy for resected non-small-cell lung cancer: Recent advances, emerging agents, and lingering questions (2004) (0)
- Dual immune checkpoint blockade in advanced well-differentiated neuroendocrine tumors, a phase II clinical trial. (2021) (0)
- 16 – Humoral and Cellular Immune Dysregulation and Lung Cancer (2018) (0)
- P3.03-007 LCMC2: Expanded Profiling of Lung Adenocarcinomas Identifies ROS1 and RET Rearrangements and TP53 Mutations as a Negative Prognostic Factor (2017) (0)
- Socio-economic status and social isolation as determinants of survival in non-small cell lung cancer (2007) (0)
- Association between baseline tumor dimensions and survival in advanced non-small cell lung cancer (NSCLC). (2013) (0)
- 366 Evaluation of Gefitinib biological effects in patients with solid tumors amenable to sequential biopsies (2004) (0)
- Abstract 4041: Coupling neoantigen specific T cell clonotypes and their molecular phenotypes at the single cell level in resectable anti-PD-1 treated NSCLC (2019) (0)
- Abstract 538: Liquid biopsy approaches for determining pathologic response to neoadjuvant immunotherapy in esophageal cancer (2021) (0)
- Update in Oncology (2005) (0)
- P-242 HIV and lung cancer patients: Why such poor survival? (2005) (0)
- CheckMate 227: Nivolumab + Ipilimumab vs Chemotherapy as 1L Treatment for Advanced NSCLC With High Tumor Mutational Burden: PS2 (2018) (0)
- Abstract CT572: Phase 1b dose-escalation and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd) in combination with durvalumab and cisplatin, carboplatin, or pemetrexed in advanced or metastatic, HER2-overexpressing, nonsquamous non-small cell lung cancer (NSCLC): DESTINY-Lung03 (2022) (0)
- FP07.05 DREAM3R: Durvalumab With Chemotherapy as First Line Treatment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial (2021) (0)
- Lung tumor-infiltrating Treg have divergent transcriptional profiles and function linked to checkpoint blockade response (2022) (0)
- OA20.02 Neoantigen Targeting in NSCLC Patients with Complete Response to Anti-PD-1 Immunotherapy (2017) (0)
- Gemcitabine (G) and vinorelbine (V) in patients (pts) with recurrent advanced non-small cell lung cancer (NSCLC): Sequence of administration matters. (2006) (0)
- 296 A comprehensive clinical and genomic characterization of long-term responders receiving immune checkpoint blockade for metastatic non-small cell lung cancer (2021) (0)
- Immunotherapy for Lung Cancer and Malignant Pleural Mesothelioma (2021) (0)
- Reply: Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors (2010) (0)
- Abstract 5902: Integrative genomic analysis of checkpoint blockade in lung cancer: A multi-institution SU2C collaborative (2020) (0)
- Abstract 3580: Integrative genomics of checkpoint blockade response in advanced non-small cell lung cancer (2022) (0)
- M06-03: Prediction of benefit from EGFR TKIs by proteomic analysis of pretreatment serum (2007) (0)
- PC02.03 IO Should Be Given as a Single Agent (2019) (0)
- A multidisciplinary immune-related toxicity (IR-Tox) program for immune-related adverse events: A two-year experience. (2020) (0)
- Clinical and molecular characteristics of advanced esophageal/GEJ cancer with brain metastasis. (2022) (0)
- PS01.61: Registry for the EVolution Of LUng Cancer Therapy Implementation and Outcomes Now (REVOLUTION): Registry Study in Progress: Topic: Medical Oncology (2016) (0)
- Abstract 1393: Persistent mutation burden drives sustained anti-tumor immune responses in human cancers (2023) (0)
- OA15.06 Pooled Analysis of Outcomes with Second-Course Pembrolizumab Across 5 Phase 3 Studies of Non-Small-Cell Lung Cancer (2022) (0)
- CTLA-4 inhibitor: Ipilimumab for the treatment of NSCLC (2012) (0)
- P3.01-70 Meta-Analysis of Metformin in Combination with Platinum Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer (2018) (0)
- Impact of prior radiation on survival in metastatic lung cancer ECOG-ACRIN trials. (2017) (0)
- Abstract 4596: Early noninvasive prediction of response to targeted therapy in non-small cell lung cancer (2018) (0)
- PPD04.02 First-Line Nivolumab + Ipilimumab (NIVO+IPI) in Metastatic NSCLC: 5-Year Survival in CheckMate 227 (2023) (0)
- Book Review Malignant Mesothelioma: Advances in Pathogenesis, Diagnosis, and Translational Therapies Edited by Harvey I. Pass, Nicholas J. Vogelzang, and Michele Carbone. 854 pp., illustrated. New York, Springer-Verlag, 2005. $139. 0-387-22949-3 (2006) (0)
- Reply to D.L. Kimpel et al. (2018) (0)
- 32 – Pleural and pericardial effusions (2011) (0)
- Meaningful Subset Analyses Contribute to Optimal Patient Care (2008) (0)
- Detection of a Macrophage Population with Distinct Gene Expression in Patients with Checkpoint Inhibitor Pneumonitis (2022) (0)
- 41P Efficacy of first-line (1L) nivolumab (N) + ipilimumab (I) by tumor histologic subtype in patients (pts) with metastatic nonsquamous NSCLC (mNSQ-NSCLC) (2023) (0)
- P21.04 Comparing Outcomes for Patients Receiving Chemoradiation Followed by Surgery vs. Immune Checkpoint Inhibitors in Non Small Cell Lung Cancer (2021) (0)
- Abstract 5033: Azacitidine pretreatment sensitizes NSCLC cells to interferon-γ (2015) (0)
- Abstract 27: Early dynamics in peripheral blood immune cell subsets and ctDNA are predictive of outcome to immunotherapy (2021) (0)
- Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology (2023) (0)
- Erratum: The role of topotecan in the treatment of small cell lung cancer (Oncologist (1998) 3 (11-14)) (1998) (0)
- Immunomodulation of Checkpoints Resets Immune System in NSCLC (2014) (0)
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab (2023) (0)
- P05.04 Association of Lymphopenia and Disease Progression in Unresectable NSCLC Treated with Definitive Chemoradiation and Immunotherapy (2021) (0)
- Abstract 4682: Sunitinib (SU) in advanced NSCLC: Correlation of circulating biomarkers with clinical outcome (2010) (0)
- Phase I Trial of Intravenous Mistletoe Extract in Advanced Cancer (2023) (0)
- Abstract LB-154: Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small cell lung carcinoma (NSCLC): A proposal for quantitative immune-related pathologic response criteria (irPRC) (2018) (0)
- Outcomes of immunotherapy-related hepatotoxicity from a multi-disciplinary toxicity team (2022) (0)
- Combined Modality Treatment of Small-Cell Lung Cancer (2003) (0)
- Commentary (Brahmer): Chemotherapy for Non–Small-Cell Lung Cancer (2003) (0)
- Long-term benefits of combined immunotherapy over chemotherapy in non-small cell lung cancer (2022) (0)
- Abstract 3957: Optimized plasma collection procedures for liquid biopsy analyses in cancer (2016) (0)
- Abstract 1617: Sex-specific genomic determinants of response to immunotherapy (2021) (0)
- Commentary (Brandes/Brahmer): Perspectives on Salvage Therapy for Non–Small-Cell Lung Cancer (2005) (0)
- 327 Development and validation of a neoantigen-specific T cell gene signature to identify antitumor T cells in lung cancer and melanoma (2021) (0)
- Immune checkpoint inhibition in elderly non-small cell lung cancer patients. (2018) (0)
- Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis (2022) (0)
- Correction to: persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1 (Journal for Immuno Therapy of Cancer (2019) 7 (40) DOI: 10.1186/s40425-018-0492-x) (2019) (0)
- Phase II trial of gemcitabine/carboplatin (GC) followed by paclitaxel (P) in patients with performance status = 2,3 or other significant co-morbidity (HIV infection or s/p organ transplantation) in advanced non-small cell lung cancer (NSCLC) (2007) (0)
- Abstract 3668: ctDNA and TCR dynamics predict response toimmune checkpoint blockade in non-small cell lung cancer (2018) (0)
- AACR: Lung Cancer Therapy Innovations (2013) (0)
- 187P Phase I/II study of the oral CCR4 antagonist, FLX475, as monotherapy and in combination with pembrolizumab in advanced cancer (2022) (0)
- Abstract 3278: Identification of epigenetic therapy induced tumor antigens to promote proliferation and infiltration of antigen specific T cells in non-small cell lung cancer (2022) (0)
- Malignancy-Related Effusions (2020) (0)
- Perspectives on salvage therapy for non-small-cell lung cancer: Commentary (2005) (0)
- Epigenetic therapy inhibits metastases by disrupting premetastatic niches (2020) (0)
- P2.03a-010 A Randomized Phase II Study of Platinum-Based Chemotherapy +/- Metformin in Chemotherapy-Naïve Advanced Non-Squamous NSCLC: Topic: Clinical Trials (2017) (0)
- Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non-small-cell lung cancer. (2023) (0)
- Abstract LB197: An SU2C-Mark Foundation Lung collaborative update: integrative genomics identifies distinct transcriptional states associated with checkpoint blockade resistance (2021) (0)
- Abstract CT212: A ctDNA-directed, multi-center phase II study of molecular response adaptive immuno-chemotherapy in patients with non-small cell lung cancer: Analysis of Stage 1 of CCTG BR.36 (2023) (0)
- Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer (2023) (0)
- Abstract 1668: Longitudinal dynamics of circulating tumor DNA and plasma proteomics predict clinical outcomes to immunotherapy in non-small cell lung cancer (2021) (0)
- Abstract 4483: Distinct spatial distribution patterns of ALK-inhibitor naïve versus ALK-inhibitor treated ALK-positive NSCLC brain metastases (2023) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Julie Renee Brahmer?
Julie Renee Brahmer is affiliated with the following schools:
